Skip to main content
. 2013 Jan 25;8(1):e53131. doi: 10.1371/journal.pone.0053131

Figure 5. Inhibition of IL-17A at tumor sites reduces MDSCs and Treg cells in the tumor microenvironment.

Figure 5

(A) Splenocytes and TILs were collected from spleens or tumor tissues of MC38 subcutaneous tumor model. Treg cells were detected by intracellular staining assay of anti-Foxp3 mAb. Representive flow cytometry analysis profiles gated on anti-CD3 and anti-CD4 mAb. Ad-si-IL-17 treatment decreased the ratio of Treg cells in TILs, but those in splenocytes were similar in both treatments. Data are representative of two independent experiments (n = 5). (B) Splenocytes and TILs were collected from spleens or tumor tissues of the MC38 subcutaneous tumor model. MDSCs cells were detected by double-staining of anti-CD11b mAb and anti-Gr1 mAb. Representive flow cytometry analysis profiles gated on anti-CD45 mAb. Ad-si-IL-17 treatment decreased the ratio of MDSCs in TILs, but those in splenocytes were at similar levels in both treatments. Data are representative of two independent experiments (n = 5). (C) Levels of IL-6 and CCL2 protein were measured in tumor lysates from mice at 14 d after having been treated with Ad-SNC, or Ad-si-IL-17. IL-6 and CCL2 were significantly decreased in tumors from Ad-si-IL-17–injected mice compared with control mice. Data are presented as means ± SE (n = 5). *P<0.05, Student's t test.